IDL Biotech meddelar att de har tecknat ett avtal med Beckman Coulter om licensiering av IDL Biotechs samtliga tumörmarkörer på den manuella plattformen radioimmunoassay (IRMA). Licensavtalet ger Beckman Coulter globala försäljningsrättigheter och möjliggör för IDL att erhålla royalties. Avtalet har formellt undertecknats av Immunotech, ett dotterbolag till Beckman Coulter.
Läs pressmeddelandet här.
During CACLP in Xiamen, China’s largest IVD exhibition, IDL Diagnostics had the opportunity to meet a wide range of industry players, exchange valuable insights, and further explore the fast-evolving Chinese IVD market. The trip concluded in Tianjin with our first...
Anders Hultman, Gustav Sten, Xia Jiang and Marie Torstensson have been in Shanghai, China, to meet our partners within CLIA. Currently, we have one product on the market, TPS CLIA, as well as two products in development: TK1 CLIA and UBC CLIA. The purpose of the...
IDL Diagnostics attended the European Association of Urology (EAU) 2026 conference in London last week. We had valuable discussions with physicians who use our diagnostic biomarkers in clinical practice and research. A big thank you to everyone we met at EAU26! We...
